- Home
- AURA vs EBS Comparison
AURA vs EBS Comparison
Compare AURA & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AURA
- EBS
- Stock Information
- Founded
- AURA 2007
- EBS 1998
- Country
- AURA United States
- EBS United States
- Employees
- AURA N/A
- EBS N/A
- Industry
- AURA Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- AURA Health Care
- EBS Health Care
- Exchange
- AURA Nasdaq
- EBS Nasdaq
- Market Cap
- AURA 396.8M
- EBS 359.3M
- IPO Year
- AURA 2021
- EBS 2006
- Fundamental
- Price
- AURA $6.57
- EBS $7.52
- Analyst Decision
- AURA Strong Buy
- EBS Strong Buy
- Analyst Count
- AURA 7
- EBS 3
- Target Price
- AURA $22.29
- EBS $14.33
- AVG Volume (30 Days)
- AURA 139.6K
- EBS 1.2M
- Earning Date
- AURA 08-13-2025
- EBS 11-05-2025
- Dividend Yield
- AURA N/A
- EBS N/A
- EPS Growth
- AURA N/A
- EBS N/A
- EPS
- AURA N/A
- EBS 2.53
- Revenue
- AURA N/A
- EBS $851,600,000.00
- Revenue This Year
- AURA N/A
- EBS N/A
- Revenue Next Year
- AURA N/A
- EBS $19.24
- P/E Ratio
- AURA N/A
- EBS $3.00
- Revenue Growth
- AURA N/A
- EBS N/A
- 52 Week Low
- AURA $4.35
- EBS $4.02
- 52 Week High
- AURA $12.38
- EBS $12.73
- Technical
- Relative Strength Index (RSI)
- AURA 50.72
- EBS 40.70
- Support Level
- AURA $6.20
- EBS $8.16
- Resistance Level
- AURA $6.80
- EBS $8.62
- Average True Range (ATR)
- AURA 0.29
- EBS 0.36
- MACD
- AURA -0.00
- EBS -0.23
- Stochastic Oscillator
- AURA 67.14
- EBS 3.16
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.